A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma

British Journal of Haematology

Volumn 161, Issue 2, 2013, Pages 183-191

  Budde, Lihua E ^a,b,e   Zhang, Michelle M ^c   Shustov, Andrei R ^a,b   Pagel, John M ^a,b   Gooley, Ted A ^a,b   Oliveira, George R ^d   Chen, Tara L ^b   Knudsen, Nancy L ^a   Roden, Jennifer E ^b   Kammerer, Britt E ^a   Frayo, Shani L ^a   Warr, Thomas A ^e   Boyd, Thomas E ^f   Press, Oliver W ^a,b   Gopal, Ajay K ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Valley Medical Center   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Pharmacy Services University of Washington ^*  (United States)

^f Yakima Regional Medical and Cardiac Center   (United States)

Author keywords

2 stage design; Clinical trial; Lymphoma; Phase I; Vorinostat

Indexed keywords

APREPITANT; ATROPINE PLUS DIPHENOXYLATE; CARBOPLATIN; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; LOPERAMIDE; ONDANSETRON; PALONOSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VORINOSTAT;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN DISEASE; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CONFUSION; CYTOPENIA; CYTOTOXICITY; DEEP VEIN THROMBOSIS; DEHYDRATION; DELIRIUM; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; ENZYME ACTIVITY; ENZYME INHIBITION; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HALLUCINATION; HEMORRHOID; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYPERCALCEMIA; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; IN VITRO STUDY; INFECTION; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; LYMPHOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; OPEN STUDY; PAIN; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; ULCER; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG SYNERGISM; ETOPOSIDE; FEMALE; HUMANS; HYDROXAMIC ACIDS; IFOSFAMIDE; LYMPHOMA; MALE; MIDDLE AGED;

EID: 84875813981     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12230     Document Type: Article

References (28)

1. Armitage, J.O. (2010) Early-stage Hodgkin's lymphoma. The New England Journal of Medicine, 363, 653-662.
2. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-López, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 17, 1244.
3. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346, 235-242.
4. Dickson, M.A., Rathkopf, D.E., Carvajal, R.D., Grant, S., Roberts, J.D., Reid, J.M., Ames, M.M., McGovern, R.M., Lefkowitz, R.A., Gonen, M., Cane, L.M., Dials, H.J. & Schwartz, G.K. (2011) A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational New Drugs, 29, 1004-1012.
5. Ellis, L., Hammers, H. & Pili, R. (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Letters, 280, 145-153.
6. Engert, A., Diehl, V., Franklin, J., Lohri, A., Dörken, B., Ludwig, W.-D., Koch, P., Hänel, M., Pfreundschuh, M., Wilhelm, M., Trümper, L., Aulitzky, W.-E., Bentz, M., Rummel, M., Sezer, O., Müller-Hermelink, H.-K., Hasenclever, D. & Löffler, M. (2009) Escalated-dose beacopp in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the ghsg hd9 study. Journal of Clinical Oncology, 27, 4548-4554.
7. Fisher, R.I., LeBlanc, M., Press, O.W., Maloney, D.G., Unger, J.M. & Miller, T.P. (2005) New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma. Journal of Clinical Oncology, 23, 8447-8452.
8. Frew, A.J., Johnstone, R.W. & Bolden, J.E. (2009) Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Letters, 280, 125-133.
9. Gisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D.C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., Ma, D., Brière, J., Moskowitz, C.H. & Schmitz, N. (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 4184-4190.
10. Gul, H., Marquez-Curtis, L.A., Jahroudi, N., Lo, J., Turner, A.R. & Janowska-Wieczorek, A. (2009) Valproic acid increases CXCR4 expression in hematopoietic stem/progenitor cells by chromatin remodeling. Stem Cells and Development, 18, 831-838.
11. Hansen, M.B., Nielsen, S.E. & Berg, K. (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. Journal of Immunological Methods, 119, 203-210.
12. Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Reiser, M., Forstpointner, R., Metzner, B., Peter, N., Wörmann, B., Trümper, L., Pfreundschuh, M., Einsele, H., Hiddemann, W., Unterhalt, M. & Dreyling, M. (2009) Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma. Journal of Clinical Oncology, 27, 511-518.
13. Kelly, W.K., O'Connor, O.A., Krug, L.M., Chiao, J.H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J.P., Schwartz, L., Richardson, S., Chu, E., Olgac, S., Marks, P.A., Scher, H. & Richon, V.M. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of Clinical Oncology, 23, 3923-3931.
14. Kewalramani, T., Zelenetz, A.D., Nimer, S.D., Portlock, C., Straus, D., Noy, A., O'Connor, O., Filippa, D.A., Teruya-Feldstein, J., Gencarelli, A., Qin, J., Waxman, A., Yahalom, J. & Moskowitz, C.H. (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 103, 3684-3688.
15. Kim, M.S., Kwon, H.J., Lee, Y.M., Baek, J.H., Jang, J.E., Lee, S.W., Moon, E.J., Kim, H.S., Lee, S.K., Chung, H.Y., Kim, C.W. & Kim, K.W. (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nature Medicine, 7, 437-443.
16. Maeda, T., Towatari, M., Kosugi, H. & Saito, H. (2000) Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood, 96, 3847-3856.
17. Marchion, D.C., Bicaku, E., Daud, A.I., Richon, V., Sullivan, D.M. & Munster, P.N. (2004) Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. Journal of Cellular Biochemistry, 92, 223-237.
18. Marks, P.A., Richon, V.M., Breslow, R. & Rifkind, R.A. (2001) Histone deacetylase inhibitors as new cancer drugs. Current Opinion in Oncology, 13, 477-483.
19. Menzies, B.E. & Kenoyer, A. (2006) Signal transduction and nuclear responses in Staphylococcus aureus-induced expression of human beta-defensin 3 in skin keratinocytes. Infection and Immunity, 74, 6847-6854.
20. Moskowitz, C.H., Bertino, J.R., Glassman, J.R., Hedrick, E.E., Hunte, S., Coady-Lyons, N., Agus, D.B., Goy, A., Jurcic, J., Noy, A., O'Brien, J., Portlock, C.S., Straus, D.S., Childs, B., Frank, R., Yahalom, J., Filippa, D., Louie, D., Nimer, S.D. & Zelenetz, A.D. (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. Journal of Clinical Oncology, 17, 3776-3785.
21. Parise, R.A., Holleran, J.L., Beumer, J.H., Ramalingam, S. & Egorin, M.J. (2006) A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 840, 108-115.
22. Ramalingam, S.S., Parise, R.A., Ramananthan, R.K., Lagattuta, T.F., Musguire, L.A., Stoller, R.G., Potter, D.M., Argiris, A.E., Zwiebel, J.A., Egorin, M.J. & Belani, C.P. (2007) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clinical Cancer Research, 13, 3605-3610.
23. Rikiishi, H., Shinohara, F., Sato, T., Sato, Y., Suzuki, M. & Echigo, S. (2007) Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. International Journal of Oncology, 30, 1181-1188.
24. Rubin, E.H., Agrawal, N.G.B., Friedman, E.J., Scott, P., Mazina, K.E., Sun, L., Du, L., Ricker, J.L., Frankel, S.R., Gottesdiener, K.M., Wagner, J.A. & Iwamoto, M. (2006) A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clinical Cancer Research, 12, 7039-7045.
25. Storer, B.E. (2001) An evaluation of phase I clinical trial designs in the continuous dose-response setting. Statistics in Medicine, 20, 2399-2408.
26. Swenson, W.T., Wooldridge, J.E., Lynch, C.F., Forman-Hoffman, V.L., Chrischilles, E. & Link, B.K. (2005) Improved survival of follicular lymphoma patients in the united states. Journal of Clinical Oncology, 23, 5019-5026.
27. Viviani, S., Zinzani, P.L., Rambaldi, A., Brusamolino, E., Levis, A., Bonfante, V., Vitolo, U., Pulsoni, A., Liberati, A.M., Specchia, G., Valagussa, P., Rossi, A., Zaja, F., Pogliani, E.M., Pregno, P., Gotti, M., Gallamini, A., Rota Scalabrini, D., Bonadonna, G. & Gianni, A.M. (2011) ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. The New England Journal of Medicine, 365, 203-212.
28. Zhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., Sun, J., Yu, Y., Zhou, W., Zheng, Q., Wu, M., Otterson, G.A. & Zhu, W.-G. (2006) Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Molecular and Cellular Biology, 26, 2782-2790.